Hennion & Walsh Asset Management, Inc. Beyond Spring Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$0.75 - $1.16 $11,992 - $18,548	-15,990 Reduced 16.49%	80,993 $64,000
Q2 2023 Aug 09, 2023	BUY	$0.89 - $1.39 $907 - $1,417	1,020 Added 1.06%	96,983 $114,000
Q1 2023 Apr 20, 2023	SELL	$1.06 - $3.05 $2,390 - $6,877	-2,255 Reduced 2.3%	95,963 $107,000
Q4 2022 Jan 12, 2023	BUY	$0.56 - $2.61 $4,383 - $20,431	7,828 Added 8.66%	98,218 $185,000
Q3 2022 Nov 14, 2022	SELL	$0.97 - $1.81 $2,938 - $5,482	-3,029 Reduced 3.24%	90,390 $89,000
Q2 2022 Jul 19, 2022	BUY	$1.13 - $2.66 $10,182 - $23,969	9,011 Added 10.68%	93,419 $135,000
Q1 2022 Apr 26, 2022	BUY	$1.68 - $5.01 $55,986 - $166,958	33,325 Added 65.24%	84,408 $186,000
Q4 2021 Feb 14, 2022	BUY	$4.02 - $16.84 $205,353 - $860,237	51,083 New	51,083 $231,000

5.55M

26K

2.4K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $66.6M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.